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Background/aim: This study analyzed the incidence, trends, and common types of cancer in the Turkish Republic of Northern Cyprus
(TRNC).
Materials and methods: This study is based on data collected from the office of the North Cyprus Cancer Registry, Ministry of Health,
for 2007–2012. Data were arranged on the basis of age group, sex, and cancer site. Age standardized incidence rates (ASRs) were
estimated with the world standard population. EVIEWS (version 9) software was used for statistical analysis.
Results: Of 1395 registered cases, 52.33% (730) were reported in men and 47.67% (665) in women. The crude incidence rate was 96.41
in men and 101.74 in women. The average annual ASR was 88.88 in men and 87.76 in women with the cumulative rate of 21.47% and
14.69% in men and women, respectively. The most common cancers in men were skin (ASR 15.62), prostate (ASR 11.23), bladder (ASR
11.71), lung (ASR 8.01), and colorectal cancer (ASR 7.61), while in women these were breast (ASR 24.07), thyroid (ASR 14.93), skin
(ASR 10.75), colorectal (ASR 6.05), and lymphoma (ASR 4.79). Linear regression analysis confirmed rising trends for both men’s (10.79,
P ≤ 0.03) and women’s (14.67, P ≤ 0.04) cancers.
Conclusion: Our findings revealed an increasing trend of cancer incidence in the TRNC. For control and prevention, public awareness
of the risk factors and proper screening programs should be recommended.
Key words: Cancer incidence, age standardized rate, cumulative rate, cumulative risk, North Cyprus

1. Introduction
Cancer is a major health issue as a leading cause of
death worldwide (1). The global cancer burden is
expected to rise by as much as 70% within the next two
decades if preventive measures are not implemented
(2). Cancers that once were considered the main cause
of morbidity and mortality in economically developed
countries such as breast, lung, and colon cancer are
now frequently diagnosed in developing countries with
a higher rate. In recent years alarming trends in cancer
incidence rates have been reported in most countries
(3,4).
Although the mortality rate has declined, cancer
is now the second most important cause of death in
Europe; approximately 20%–40% of world cancer
deaths are associated with this region. More than three
million new cases (54% in men and 46% in women)
are registered in Europe each year (5). However,
there are great variations in cancer incidences in
different European countries, being highest in
* Correspondence: ruqiyapervaiz@awkum.edu.pk

northern and western parts of Europe while lower in
some Mediterranean countries. Prostate cancer is the
most common cancer of men in almost all European
countries except a few eastern and central countries,
whereas lung cancer is still the most common. Among
women the breast is the primary site of cancer with the
highest incidence rate in western Europe (6,7).
A limited number of studies on cancer incidence
have been conducted in the Turkish Republic of
Northern Cyprus (TRNC) with a population of
approximately 0.3 million (8). However, there is
insufficient information on the recent changes in the
incidence of common cancer types.
For control and prevention of cancer, both incidence
and time-trend analysis are important. Therefore, this
study aimed to outline crucial information for policymakers and decision-makers, stakeholders, cancer
researchers, and residents of the TRNC. This study
investigated the incidence of cancer and the most
commonly occurring types in the TRNC.
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2. Materials and methods
This analytical study was carried out based on data
collected from the North Cyprus Cancer Registry (NCCR),
TRNC Ministry of Health, for the years 2007, 2008, 2009,
2011, and 2012. The year 2010 is not included in this study
since data were not available in the registry. Additionally,
no data were recorded after the year 2012 in the registry.
Data sets were arranged on the bases of age groups,
sex, and cancer types. Cases with secondary tumors are
not included in this study. Only residents of the TRNC
with a minimum stay of 6 months before the diagnosis are
included in this study.
2.1. Grouping of data
Data analysis was performed separately for men and
women in respect to the most common cancer types.
2.2. Parameters studied
2.2.1. Crude rate
Crude incidence rate is used to predict cancer incidence for
the current period and is applied to the current population.
For each cancer type, crude rate (CR) per 100,000 is
calculated by dividing the total cases of respective type
by total population: CR = R/N × 100,000, where R = total
number of cases and N = total number of person-years (9).
2.2.2. Age standardized rate per 100,000 with world
standard population (ASR-W)
Countries with a high proportion of older population have
a high percentage of cancer incidence (78% in developed
countries) as compared to countries with a high proportion
of younger population (58% in developing countries) (10).
In such cases, comparisons of crude incidence rates give
false outcomes. Therefore, ASR estimation per 100,000
allows for changing population age structure. Standardized
incidence rates were calculated by direct standardization
method with the world standard population as previously
described (11–13). Population values of the TRNC
were obtained from census data statistical yearbooks
for the years 2007, 2008, 2009, 2011, and 2012 from the
State Planning Organization Statistics and Research
Department. Variance (Var. ASR) and standard error (S.e.
ASR) of age standardized incidence rate were obtained by
binomial approximation and 95% confidence intervals
(C.I.) were calculated. The formulas used were:
ASR =

Σ
Σ

A
i=1

ai wi

A
i=1

Var (ASR) =

wi

Σ

A
i=1

(ai w2i(100 000-ai)/ni)
(Σi=1 wi)
A

2

S.e. (ASR) = Var (ASR)
C.I. = ASR ± Za/2 × (S.e. (ASR)) (9).
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R = Total number of cases.
N = Total number of person-years.
Σ = Summation, which means the sum of every term in
the equation after the summation sign.
ai = Age specific rate per 100,000 in each age group.
wi = World standard population in each age group.
ni = Person-years (every term in the set).
Za/2 = 1.69.
2.2.3. Cumulative rate and cumulative risk
The cumulative rate (the sum over each year of age of the
age-specific incidence rate taken from birth to age 74,
0–74 rate) and the cumulative risk (the risk of developing a
specific type of cancer at a certain age in the absence of any
other cause of death) were calculated with the following
formulas:
Cum. rate (0–74) = Σ (age-specific rate × length of age
class)
Cum. risk = 100 × (1 –exp (–cum. rate/100)) (14).
The 95% confidence intervals were calculated with the
following formula:
C.I. = Cum. rate ASR ± Za/2 × (S.e. (cum. rate)) (9).
2.3. Statistical analysis
Statistical analysis was performed with Excel and EVIEWS
(version 9) software. A simple regression model was
estimated to calculate the simple linear slope of the annual
increase. The significance level was considered as P ≤ 0.05.
3. Results
In this study, a total of 1395 registered cancer cases have
been analyzed between the years 2007 and 2012 (excluding
2010). Of the total registered cases, 730 (52.33%) patients
were men and 665 (47.67%) were women. The ASR of
cancer showed an increased trend in men as well as in
women for the study period of 2007 to 2012. For men,
the ASR in 2007 was 71.09 with a rise to 110.12 in 2012.
Similarly for women, the ASR in 2007 was 66.04 with an
increase to 120.93 in 2012. The highest cancer incidence
rate for both sexes was seen in 2011 while the lowest was
in 2008 (Table 1).
In men, the most common types of cancer were skin
(17% of the total), prostate (12.6%), bladder (12.6%),
lung (8.8%), and colorectal (8.63%), while in women they
were breast (27.82%), thyroid (16.69%), skin (12.03%),
colorectal (7.07%), and lymphoma cancer (5.11%) (Figure
1).
Linear regression analysis indicated a significantly
incremental linear slope (10.79) for ASR of cancer for men
(P ≤ 0.03). Linear regression was also significant for ASR
of women with an increasing slope of 14.67 (P ≤ 0.04)
(Figures 2 and 3).
The crude incidence rate per 100,000 population was
96.41 in men and 101.74 in women, while the average
annual ASR for men was 88.88 ± 6.56 and for women was

PERVAIZ et al. / Turk J Med Sci
Table 1. Year-wise number of cases and age standardized incidence rates (per 105) by sex for 2007–2012
(excluding 2010).
Year

Count (men)

Men, ASR/105

Count (women)

Women, ASR/105

2007

106

71.09

93

66.04

2008

91

59.28

81

57.35

2009

136

83.70

87

59.26

2011

207

116.52

201

125.26

2012

190

110.12

203

120.93

Figure 1. Age standardized incidence rate (per 105) for different cancer types by sex in the period 2007–2012 (excluding 2010).

87.71 ± 6.73. The cumulative incidence rate (0–74 years
old) was 21.47% in men and 14.69% in women. The risk of
developing cancer up to the age of 75 was 19.32% in men
and 13.66% in women (Table 2).
Skin cancer (melanoma and nonmelanoma collectively)
showed the highest incidence in men with ASR 15.62,
cumulative incidence rate of 3.81%, and cumulative risk
of 3.74% (Table 2).
The incidence rates of prostate and bladder cancers in
men showed some variations with ASR 11.23 and 11.71,
respectively. For prostate cancer the cumulative rate was
2.87% and the cumulative risk was 2.82%, while for bladder
cancer these were 2.78% and 2.74%, respectively. Lung and
colorectal cancers with standardized incidence rates of 8.01
and 7.61 were found to be the fourth and fifth most detected
cancer types in men. Apart from the above five, other cancer
types in men were lymphoma (ASR 6.05), stomach (ASR
4.52), liver (ASR 3.95), thyroid (ASR 2.11), kidney (ASR
1.82), and testis (ASR 1.53). In men there were also a few
registered cases of breast cancer (ASR 0.53) (Table 2).

In women, breast cancer showed the highest incidence
with standardized incidence rate of 24.07, followed by
thyroid (ASR 14.93), skin (ASR 10.75), colorectal (ASR
6.05), and lymphoma cancer (ASR 4.79). Other forms of
cancers identified in women were lung (ASR 3.07), bladder
(ASR 2.38), cervix (ASR 2.20), stomach (ASR 2.34),
endometrium (ASR 2.01), kidney (ASR 1.30), and liver
cancer (ASR 0.60) (Table 2).
Similarly, breast cancer shows the highest cumulative
incidence rate and cumulative risk for women in the
TRNC (4.0% and 3.92%, respectively) followed by thyroid
(2% both) and skin (1.5% both) cancers (Table 2).
4. Discussion
This study investigated the incidence and trend of cancer in
the TRNC between the period of 2007 and 2012 (excluding
the year 2010). Cancer incidence is on the rise worldwide;
hence, an estimated 14.1 million new cancer cases were
registered in 2012 while this number was 12.7 million in
2008 (15). In developed countries such as the United States,

525

PERVAIZ et al. / Turk J Med Sci

Figure 2. Trend of cancer incidence among men in the TRNC, 2007–2012 (excluding 2010).

Figure 3. Trend of cancer incidence among women in the TRNC, 2007–2012 (excluding 2010)

more than 50% of men and more than 30% of women have
the risk of developing cancer in their lifetime, while in
1950 this risk was 25% for both sexes (16). A similar rise
in cancer incidence was observed in many countries such
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as Belgium, Germany, Mexico, Poland, France, Turkey,
the United Kingdom, Norway, Italy, the Netherlands, and
Hungary (17). One of the possible reasons for this rise in
cancer incidence could be changes in lifestyle (smoking,
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Table 2. Crude rate, age standardized rate with world standard population (ASR-W) per 100,000 with 95% confidence interval
(C.I.), cumulative rate, and cumulative risk of 12 cancer types by sex, averaged for 5 years (2007–2012, excluding 2010), TRNC.
Crude rate

ASR-W/105 with
95% C.I.

% Cumulative rate
(0–74) with 95% C.I.

% Cumulative risk
(0–74)

Skin

16.38

15.62 ± 2.78

3.81 ± 0.12

3.74

Bladder

12.15

11.71 ± 2.42

2.78 ± 0.10

2.74

Prostate

12.41

11.23 ± 2.30

2.87 ± 0.11

2.82

Lung

8.45

8.01 ± 1.98

2.86 ± 0.11

2.82

Colorectal

8.32

7.61 ± 1.90

1.39 ± 0.06

1.38

Lymphoma

6.34

6.05 ± 0.44

1.51 ± 0.08

1.49

Stomach

4.75

4.52 ± 1.49

1.49 ± 0.08

1.48

Liver

4.23

3.95 ± 1.39

0.86 ± 0.05

0.86

Thyroid

2.25

2.11 ± 1.01

0.52 ± 0.04

0.52

Kidneys

1.85

1.82 ± 0.96

0.64 ± 0.05

0.63

Testis

1.58

1.53 ± 0.87

0.60 ± 0.05

0.60

Breast

0.53

0.53 ± 0.53

0.07 ± 0.01

0.07

All cancers: males

96.41

88.88 ± 6.56

21.47 ± 0.28

19.32

Breast

28.30

24.07 ± 3.49

4.00 ± 0.09

3.92

Thyroid

16.98

14.93 ± 1.00

2.00 ± 0.06

1.98

Skin

12.24

10.75 ± 2.38

1.49 ± 0.05

1.47

Colorectal

7.19

6.05 ± 1.75

1.28 ± 0.06

1.27

Lymphoma

5.20

4.79 ± 1.63

0.48 ± 0.02

0.48

Lung

3.52

3.07 ± 1.26

0.45 ± 0.03

0.45

Bladder

2.91

2.38 ± 1.09

0.67 ± 0.04

0.66

Stomach

2.45

2.34 ± 1.10

0.55 ± 0.04

0.55

Cervical

2.60

2.20 ± 0.38

0.53 ± 0.04

0.53

Endometrium

2.75

2.01 ± 1.00

0.52 ± 0.04

0.52

Kidneys

1.53

1.30 ± 0.81

0.25 ± 0.02

0.25

Liver

1.38

1.23 ± 0.81

0.15 ± 0.01

0.15

All cancers: females

101.74

87.71 ± 6.73

14.69 ± 0.17

13.66

Cancer type
Males

Females

obesity, low exercise, etc.) and environmental factors (18,19).
Many carcinogens present in our environment in the form of
radiation, electromagnetic waves, various types of pathogens,
parasites, viruses, chemicals, volatile organic compounds,
insecticides and pesticides, food additives, pharmaceutical
drugs, compounds in cosmetics, etc. may be among the
causes of the current increase in the incidence of cancer
worldwide (20).
The world ASR for all cancers excluding nonmelanoma
skin cancer is 202.0 in men and 165.2 in women (21). The ASR
of all types of cancers for men (88.88) and women (87.71) in
the TRNC is as low as half compared to the rest of the world.

However, the cancer incidence in the TRNC also shows
an increase, which can be clearly noticed by the regression
line showing the upward trend for the study period in both
sexes. The world cumulative risk of cancer is 20.95% in men
and 16.38% in women, while in the TRNC it is 19.32% in
men and 13.66% in women. The ASR for other cancer types
(colorectal, lung, stomach, liver, and kidney cancers in both
sexes and breast and cervical in women and prostate cancer
in men) also shows lower incidence in the TRNC than the
world for the respective types. However, bladder and thyroid
cancers in both sexes showed higher incidence in the TRNC
compared to the rest of the world (21) (Table 2).
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Hinçal et al. conducted a study on cancer incidence in
the TRNC relative to other European countries in the period
of 1990–2004. According to their findings, the common
cancers in men were lung, skin, colorectal, brain, prostate,
bladder, liver, and stomach, while in women they were
breast, gynecological, skin, colorectal, lung, liver, brain,
stomach, and bladder. Although both studies were based
on the same population-based cancer registry (NCCR), the
order of prevalence of common cancers differs in our study
and this previously published study. This difference might
be due to the different time periods of these two studies
(1990–2004 versus 2007–2012) and the improvement in
the data collection methods by the registry overtime (22).
However, it is important to note that both studies showed
breast cancer as the most common malignancy of women
and skin, bladder, and colorectal cancer were in high
prevalence among both sexes in the TRNC (23).
Breast cancer is the most prevalent type in women
worldwide with ASR 38.9 and covers about a quarter of
all types (21). Breast cancer shows an increasing trend
in European countries (24), while in Asian countries the
incidence rate of breast cancer is lower but the trend is on
rise (25). In the current study the ASR of 24.07 of breast
cancer also showed that this cancer is the most common
in women in the TRNC with high cum. risk (3.92%),
whereas for men, this cancer was shown to be rare with low
risk but still existent (0.07%; Table 2). Hormonal therapy,
having fewer children, late reproduction, early menarche,
late menopause, and obesity are considered to be the risk
factors of breast cancer (24,26). Studies also showed the
association of prolonged use of oral contraceptives with
increased risk of breast cancer (27). For men the risk
factors of breast cancer are similar to those for women,
including estrogen changes, decreased levels of androgens,
benign breast disease, liver and testes disease, Klinefelter
syndrome, family history, and exposure to ionization
radiations (X-rays, UV rays, etc.), and an obese man has
3–5 times more breast cancer risk than a man of average
weight (28).
This study indicated thyroid cancer as the second most
prevalent cancer in women in the TRNC after breast cancer
with cum. risk of 2.0%. This high incidence of thyroid
cancer in women (ASR 14.93) as compared to men (ASR
2.11) requires further investigations to determine whether
these findings represent a true increase that could be due to
some sort of radiation exposure or are due to frequent use
of fine-needle biopsies and ultrasound for small papillary
tumor detection (29). A recent report by Farazi also showed
a higher rate for thyroid cancer in female Cypriots and
reported that the incidence was doubled in just one decade,
from 1998 to 2008 (24). Furthermore, the incidence of
thyroid cancer has increased in the recent years in other
European countries, as well (30). The main risk factors for
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thyroid cancer are exposure to ionized radiation, mostly in
childhood, and a history of thyroid nodules (31).
This study showed a higher incidence rate of skin
cancer in both men and women in the TRNC (the 1st
most prevalent in men and 3rd in women) with a higher
cumulative risk. Skin cancer has been diagnosed with
high frequency among men in some parts of the world
like New Guinea, Australia, Ireland (32), and Iran (19,33).
In 2013 the American Cancer Society reported a link
between ultraviolet radiation (UVR) and skin cancer
(34). In Cyprus the UVR is considered to be on the high
end. Due to the year-round sunshine, the daily ambient
UVR level for Cyprus is higher than other countries of
the Mediterranean region (35). Other common types of
cancer in the TRNC include prostate, bladder, colorectal,
lung, liver, kidney, and lymphoma (Hodgkin and nonHodgkin lymphomas).
Although both lung and bladder cancers are
smoking-related, bladder cancer showed a higher ASR
as compared to lung cancer in the TRNC. However, as
reported previously, genetic and epigenetic alterations
in bladder carcinogenesis are linked to environmental
and occupational factors and account for a large number
of bladder cancer cases in nonsmokers. The interaction
between environment and inheritance modulates risk
factors for bladder cancer and influences the differing
incidences in different populations (36).
Prostate cancer is the third most common cancer
among men in TRNC and the second most common in
the world, with the highest incidence rate in developed
countries (15). The literature is limited about the
etiological factors associated with the development and
progression of prostate cancer; however, similar to the
other cancer types, genetic as well environmental factors
contribute to prostate cancer. Older age, family history,
and race (African) are the established risk factors (37).
Evidence showed that diet and lifestyle mostly affect the
risk factors of prostate cancer (38). Other studies found
that there is an association between tobacco smoking and
the development of many malignancies including larynx,
pharynx, esophagus, stomach, pancreas, bladder, uterus,
cervix, ovary, and acute myeloid leukemia (39). Tobacco
smoking is the main risk factor for triggering cancer and
is responsible for 20% of cancer deaths worldwide (2).
These tobacco-related cancers show lower incidence rates
in Cyprus as compared to other countries of the world
(e.g., the United States and United Kingdom) (24). The
detailed smoking status of men and women in the TRNC
is not known; however, western lifestyle and behavior in
addition to genetic predisposition also play a major role in
developing such types of cancers (40).
Gynecological cancer (endometrium and cervical)
in women showed lower frequency as compared to
other types but still has a cumulative risk of 0.52% for
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endometrial and 0.53% for cervical cancer in women.
The etiology of gynecological cancer is not fully known;
however, some studies showed a relation between human
papilloma virus infection and cervical cancer (41), while
increased numbers of ovarian cycles, abortions, and live
births are associated with elevated risks of endometrial
cancer (42).
In conclusion, the study findings reveal that cancer
incidence showed an increasing trend in the TRNC. Skin
cancer in men and breast cancer in women exhibited

the highest incidence rates and cumulative risk during
this 5-year study. They may be the result of exposure to
various risk factors in addition to genetic predisposition.
Further studies are required to elucidate the risk factors
that are associated with the most prevalent cancers in the
TRNC. For cancer control and prevention implementing
population-based screening programs, fostering public
awareness about the risk factors, and encouraging people
for regular screening of the breasts, thyroid, and prostate
are recommended.
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